Studies found that tumor-infiltrating lymphocytes (TILs), such as CD8+ T cells and CD3+ T cells, up-regulated the expression of the markers of immunomodulator, which may affect the efficacy of immunotherapy and associate with a poor prognosis in NSCLC [5, 6]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.